Advances in Management of Difficult‐to‐Treat Asthma: Overcoming Challenges in Rural and Underserved Settings

This program has expired.

Jointly provided by RME Collaborative and Postgraduate Institute for Medicine.

Release date: January 28, 2021

Expiration date: January 28, 2022

Estimated time to complete: 15 minutes per module

Program Overview
Asthma is a significant public health problem with a high disease burden. Increased emphasis on improving asthma care in the rural setting is particularly important given that individuals living in these areas have difficulty accessing specialty care due to geographic disparities and provider shortages. In these activities, expert faculty will discuss the use of asthma assessment tools, recent updates to asthma management guidelines, and biologic therapy for severe asthma. Strategies to improve personalized treatment and asthma self-management will also be reviewed.

Resources

Faculty
Meredith C. McCormack, MD, MHS
Associate Professor of Medicine
Division of Pulmonary and Critical Care Medicine
Johns Hopkins University
Baltimore, MD

Barbara P. Yawn, MD, MSc, MPH
Chief Science Officer, COPD Foundation
Professor of Family and Community Health
University of Minnesota
Minneapolis, MN

Target Audience
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

Learning Objectives

Module 1: Use of Asthma Tools for Assessment and Management: Achieving Better Care, Control, and Communication

Apply evidence-based strategies to assess and identify asthma patients with suboptimal disease control
Discuss strategies for improving asthma care and management in rural and underserved settings, including self-management education and asthma action plans

Module 2: Asthma Management: Recent Changes to Clinical Practice Guidelines

Develop a personalized treatment plan for patients with asthma based on current guidelines, recommendations, and clinical evidence

Module 3: Improving the Recognition and Individualized Management of Severe Asthma in Primary Care

Identify appropriate therapy for patients with moderate-to-severe asthma based on patient preferences, phenotypes, and comorbid conditions

Accreditation

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RME Collaborative. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Module 1: 0.25 AMA PRA Category 1 Credit^TM
Module 2: 0.25 AMA PRA Category 1 Credit^TM
Module 3: 0.25 AMA PRA Category 1 Credit^TM

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour.

Module 1: 0.25 contact hour; 0.25 pharmacology credit
Module 2: 0.25 contact hour; 0.25 pharmacology credit
Module 3: 0.25 contact hour; 0.25 pharmacology credit

How to Obtain Credit
If you wish to receive CME/CE credits, please follow the below steps for each module you complete:

Listen to the entire activity.
Go to cmeuniversity.com. In the “Find Post-Test/Evaluation by Course” field at the top of the page, enter the course code 15759.
Select the module you completed and fill out the activity evaluation form. A certificate of participation will be available to download/print immediately.

Disclosures of Conflicts of Interest
The Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Faculty
Meredith C. McCormack, MD, MHS, has disclosed the following relationships: consultant for Celgene and GlaxoSmithKline; royalties from UpToDate; steering committee for Actelion Pharmaceuticals, Inc.; adjudication committee, clinical trials, for Liquidia Technologies, Inc.; advisory board and chair, Data Safety Monitoring Board, for United Therapeutics.

Barbara P. Yawn, MD, MSc, MPH, has disclosed the following relationships: consultant for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis Pharmaceuticals, and Teva Pharmaceuticals.

Planners, Managers, and Reviewer
The RME Collaborative and PIM planners, managers, and reviewer have nothing to disclose.

Acknowledgement
This activity is supported by independent medical education grants from AstraZeneca and Sanofi Genzyme and Regeneron Pharmaceuticals.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Us
For questions regarding this CME activity, please contact:
RME Collaborative by phone, 800-913-9370 or email, info@talemhealth.com.

For questions about the accreditation of this activity, please visit www.pimed.com.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Media
Internet activity

Computer System Requirements

Operating system: Windows or Macintosh
Supported browsers: HTML5-capable browser – Internet Explorer 11, Microsoft Edge, Firefox 27+, Chrome 30+, Safari 9+
Hardware: computer, smartphone, or tablet
Broadband Internet connection: high-speed connection preferable

©RME Collaborative, a division of Talem Health, LLC 2021. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.